Clinical Trials · NCT03684642
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
- Phase
- Phase 3
- Recruitment status
- Terminated
- Sponsor
- Sanofi
- Enrollment
- 908
- Start date
- Sep 2018
- Locations
- 45 sites, 4 countries
- Primary endpoint
- Change From Baseline to Week 56 in HbA1c